http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 23 Oct 2026 09:01:54 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Tempus+AI+signs+multi-year+oncology+data+deal+with+Bristol+Myers+Squibb/27225665.html <p>Tempus AI (NASDAQ: TEM) announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY) under which Bristol Myers Squibb will license multimodal oncology data from Tempus through 2031, according to a press release from the Chicago-based company.</p><p>The agreement covers biological and clinical insight identification, drug target discovery, and therapeutic development across Bristol Myers Squibb's oncology portfolio. Under the deal, Bristol Myers Squibb becomes one of Tempus's largest licensors of de-identified oncology data.</p><p>Bristol Myers Squibb will also gain access to Tempus's Lens Platform, an AI-based platform for oncology drug development connected to GPU infrastructure. The platform is intended to allow Bristol http://www.streetinsider.com/Corporate+News/Tempus+AI+signs+multi-year+oncology+data+deal+with+Bristol+Myers+Squibb/27225665.html Fri, 23 Oct 2026 09:01:54 -0400 BMS BMY TEM http://www.streetinsider.com/Corporate+News/Tempus+AI+signs+multi-year+oncology+data+deal+with+Bristol+Myers+Squibb/27225665.html <p>Tempus AI (NASDAQ: TEM) announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY) under which Bristol Myers Squibb will license multimodal oncology data from Tempus through 2031, according to a press release from the Chicago-based company.</p><p>The agreement covers biological and clinical insight identification, drug target discovery, and therapeutic development across Bristol Myers Squibb's oncology portfolio. Under the deal, Bristol Myers Squibb becomes one of Tempus's largest licensors of de-identified oncology data.</p><p>Bristol Myers Squibb will also gain access to Tempus's Lens Platform, an AI-based platform for oncology drug development connected to GPU infrastructure. The platform is intended to allow Bristol http://www.streetinsider.com/Corporate+News/Tempus+AI+signs+multi-year+oncology+data+deal+with+Bristol+Myers+Squibb/27225665.html Fri, 23 Oct 2026 09:01:54 -0400 BMS BMY TEM http://www.streetinsider.com/Corporate+News/Tempus+AI+signs+multi-year+oncology+data+deal+with+Bristol+Myers+Squibb/27225665.html <p>Tempus AI (NASDAQ: TEM) announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY) under which Bristol Myers Squibb will license multimodal oncology data from Tempus through 2031, according to a press release from the Chicago-based company.</p><p>The agreement covers biological and clinical insight identification, drug target discovery, and therapeutic development across Bristol Myers Squibb's oncology portfolio. Under the deal, Bristol Myers Squibb becomes one of Tempus's largest licensors of de-identified oncology data.</p><p>Bristol Myers Squibb will also gain access to Tempus's Lens Platform, an AI-based platform for oncology drug development connected to GPU infrastructure. The platform is intended to allow Bristol http://www.streetinsider.com/Corporate+News/Tempus+AI+signs+multi-year+oncology+data+deal+with+Bristol+Myers+Squibb/27225665.html Fri, 23 Oct 2026 09:01:54 -0400 BMS BMY TEM http://www.streetinsider.com/Corporate+News/Pathos+AI+strikes+deals+with+Bristol+Myers+Squibb+and+Tempus+AI/27225664.html <p>Pathos AI has announced multi-year collaborations with Bristol Myers Squibb (NYSE: BMY) and Tempus AI (NASDAQ: TEM) focused on building AI-driven capabilities for Alzheimer's disease and other neurological conditions, according to a company press release.</p><p>Under a five-year, $55 million agreement, Tempus will construct a de-identified, longitudinal dataset drawn from hundreds of thousands of patients with neurological conditions. Pathos AI will license this dataset and apply its agentic AI platform, Pathos Foundry, to analyze disease biology and inform clinical trial design.</p><p>Bristol Myers Squibb is leading Pathos AI's Series E financing round, the terms of which were not disclosed. As part of http://www.streetinsider.com/Corporate+News/Pathos+AI+strikes+deals+with+Bristol+Myers+Squibb+and+Tempus+AI/27225664.html Fri, 23 Oct 2026 09:01:45 -0400 BMS BMY TEM http://www.streetinsider.com/Corporate+News/Pathos+AI+strikes+deals+with+Bristol+Myers+Squibb+and+Tempus+AI/27225664.html <p>Pathos AI has announced multi-year collaborations with Bristol Myers Squibb (NYSE: BMY) and Tempus AI (NASDAQ: TEM) focused on building AI-driven capabilities for Alzheimer's disease and other neurological conditions, according to a company press release.</p><p>Under a five-year, $55 million agreement, Tempus will construct a de-identified, longitudinal dataset drawn from hundreds of thousands of patients with neurological conditions. Pathos AI will license this dataset and apply its agentic AI platform, Pathos Foundry, to analyze disease biology and inform clinical trial design.</p><p>Bristol Myers Squibb is leading Pathos AI's Series E financing round, the terms of which were not disclosed. As part of http://www.streetinsider.com/Corporate+News/Pathos+AI+strikes+deals+with+Bristol+Myers+Squibb+and+Tempus+AI/27225664.html Fri, 23 Oct 2026 09:01:45 -0400 BMS BMY TEM http://www.streetinsider.com/Corporate+News/Pathos+AI+strikes+deals+with+Bristol+Myers+Squibb+and+Tempus+AI/27225664.html <p>Pathos AI has announced multi-year collaborations with Bristol Myers Squibb (NYSE: BMY) and Tempus AI (NASDAQ: TEM) focused on building AI-driven capabilities for Alzheimer's disease and other neurological conditions, according to a company press release.</p><p>Under a five-year, $55 million agreement, Tempus will construct a de-identified, longitudinal dataset drawn from hundreds of thousands of patients with neurological conditions. Pathos AI will license this dataset and apply its agentic AI platform, Pathos Foundry, to analyze disease biology and inform clinical trial design.</p><p>Bristol Myers Squibb is leading Pathos AI's Series E financing round, the terms of which were not disclosed. As part of http://www.streetinsider.com/Corporate+News/Pathos+AI+strikes+deals+with+Bristol+Myers+Squibb+and+Tempus+AI/27225664.html Fri, 23 Oct 2026 09:01:45 -0400 BMS BMY TEM http://www.streetinsider.com/Press+Releases/Tempus+Expands+Strategic+Collaboration+with+Bristol+Myers+Squibb/27225624.html <p> CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus’s largest licensors of de-identified oncology data.</p><p>Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world http://www.streetinsider.com/Press+Releases/Tempus+Expands+Strategic+Collaboration+with+Bristol+Myers+Squibb/27225624.html Fri, 23 Oct 2026 09:00:00 -0400 BMS BMY TEM http://www.streetinsider.com/Business+Wire/Tempus+Expands+Strategic+Collaboration+with+Bristol+Myers+Squibb/27225624.html <p> CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus’s largest licensors of de-identified oncology data.</p><p>Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world http://www.streetinsider.com/Business+Wire/Tempus+Expands+Strategic+Collaboration+with+Bristol+Myers+Squibb/27225624.html Fri, 23 Oct 2026 09:00:00 -0400 BMS BMY TEM http://www.streetinsider.com/Press+Releases/Tempus+Expands+Strategic+Collaboration+with+Bristol+Myers+Squibb/27225624.html <p> CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus’s largest licensors of de-identified oncology data.</p><p>Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world http://www.streetinsider.com/Press+Releases/Tempus+Expands+Strategic+Collaboration+with+Bristol+Myers+Squibb/27225624.html Fri, 23 Oct 2026 09:00:00 -0400 BMS BMY TEM http://www.streetinsider.com/Business+Wire/Tempus+Expands+Strategic+Collaboration+with+Bristol+Myers+Squibb/27225624.html <p> CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus’s largest licensors of de-identified oncology data.</p><p>Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world http://www.streetinsider.com/Business+Wire/Tempus+Expands+Strategic+Collaboration+with+Bristol+Myers+Squibb/27225624.html Fri, 23 Oct 2026 09:00:00 -0400 BMS BMY TEM http://www.streetinsider.com/Press+Releases/Tempus+Expands+Strategic+Collaboration+with+Bristol+Myers+Squibb/27225624.html <p> CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus’s largest licensors of de-identified oncology data.</p><p>Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world http://www.streetinsider.com/Press+Releases/Tempus+Expands+Strategic+Collaboration+with+Bristol+Myers+Squibb/27225624.html Fri, 23 Oct 2026 09:00:00 -0400 BMS BMY TEM http://www.streetinsider.com/Business+Wire/Tempus+Expands+Strategic+Collaboration+with+Bristol+Myers+Squibb/27225624.html <p> CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus’s largest licensors of de-identified oncology data.</p><p>Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world http://www.streetinsider.com/Business+Wire/Tempus+Expands+Strategic+Collaboration+with+Bristol+Myers+Squibb/27225624.html Fri, 23 Oct 2026 09:00:00 -0400 BMS BMY TEM http://www.streetinsider.com/Press+Releases/Pathos+AI+Announces+Strategic+Collaborations+with+Bristol+Myers+Squibb+and+Tempus+AI+to+Advance+AI-Driven+Drug+Development+Beginning+with+Alzheimer%E2%80%99s+Disease+and+Other+Neurological+Conditions/27225611.html <ul class="bwlistdisc"> <li> <i>Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement</i> </li> <li> <i>Pathos’s AI expertise and agentic AI platform, Foundry, combined with Bristol Myers Squibb’s (BMS) neuroscience drug development expertise to be applied to understanding disease progression and advancing new therapies</i> </li> <li> <i>BMS leads Pathos’s Series E financing and gains non-exclusive strategic access to Pathos’s AI platform, Pathos Foundry, across its broader portfolio, along with three-year exclusive rights to support its neuroscience development programs</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- Pathos AI, a clinical-stage AI and technology company advancing http://www.streetinsider.com/Press+Releases/Pathos+AI+Announces+Strategic+Collaborations+with+Bristol+Myers+Squibb+and+Tempus+AI+to+Advance+AI-Driven+Drug+Development+Beginning+with+Alzheimer%E2%80%99s+Disease+and+Other+Neurological+Conditions/27225611.html Fri, 23 Oct 2026 09:00:00 -0400 BMS BMY TEM http://www.streetinsider.com/Business+Wire/Pathos+AI+Announces+Strategic+Collaborations+with+Bristol+Myers+Squibb+and+Tempus+AI+to+Advance+AI-Driven+Drug+Development+Beginning+with+Alzheimer%E2%80%99s+Disease+and+Other+Neurological+Conditions/27225611.html <ul class="bwlistdisc"> <li> <i>Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement</i> </li> <li> <i>Pathos’s AI expertise and agentic AI platform, Foundry, combined with Bristol Myers Squibb’s (BMS) neuroscience drug development expertise to be applied to understanding disease progression and advancing new therapies</i> </li> <li> <i>BMS leads Pathos’s Series E financing and gains non-exclusive strategic access to Pathos’s AI platform, Pathos Foundry, across its broader portfolio, along with three-year exclusive rights to support its neuroscience development programs</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- Pathos AI, a clinical-stage AI and technology company advancing http://www.streetinsider.com/Business+Wire/Pathos+AI+Announces+Strategic+Collaborations+with+Bristol+Myers+Squibb+and+Tempus+AI+to+Advance+AI-Driven+Drug+Development+Beginning+with+Alzheimer%E2%80%99s+Disease+and+Other+Neurological+Conditions/27225611.html Fri, 23 Oct 2026 09:00:00 -0400 BMS BMY TEM http://www.streetinsider.com/Press+Releases/Pathos+AI+Announces+Strategic+Collaborations+with+Bristol+Myers+Squibb+and+Tempus+AI+to+Advance+AI-Driven+Drug+Development+Beginning+with+Alzheimer%E2%80%99s+Disease+and+Other+Neurological+Conditions/27225611.html <ul class="bwlistdisc"> <li> <i>Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement</i> </li> <li> <i>Pathos’s AI expertise and agentic AI platform, Foundry, combined with Bristol Myers Squibb’s (BMS) neuroscience drug development expertise to be applied to understanding disease progression and advancing new therapies</i> </li> <li> <i>BMS leads Pathos’s Series E financing and gains non-exclusive strategic access to Pathos’s AI platform, Pathos Foundry, across its broader portfolio, along with three-year exclusive rights to support its neuroscience development programs</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- Pathos AI, a clinical-stage AI and technology company advancing http://www.streetinsider.com/Press+Releases/Pathos+AI+Announces+Strategic+Collaborations+with+Bristol+Myers+Squibb+and+Tempus+AI+to+Advance+AI-Driven+Drug+Development+Beginning+with+Alzheimer%E2%80%99s+Disease+and+Other+Neurological+Conditions/27225611.html Fri, 23 Oct 2026 09:00:00 -0400 BMS BMY TEM http://www.streetinsider.com/Business+Wire/Pathos+AI+Announces+Strategic+Collaborations+with+Bristol+Myers+Squibb+and+Tempus+AI+to+Advance+AI-Driven+Drug+Development+Beginning+with+Alzheimer%E2%80%99s+Disease+and+Other+Neurological+Conditions/27225611.html <ul class="bwlistdisc"> <li> <i>Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement</i> </li> <li> <i>Pathos’s AI expertise and agentic AI platform, Foundry, combined with Bristol Myers Squibb’s (BMS) neuroscience drug development expertise to be applied to understanding disease progression and advancing new therapies</i> </li> <li> <i>BMS leads Pathos’s Series E financing and gains non-exclusive strategic access to Pathos’s AI platform, Pathos Foundry, across its broader portfolio, along with three-year exclusive rights to support its neuroscience development programs</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- Pathos AI, a clinical-stage AI and technology company advancing http://www.streetinsider.com/Business+Wire/Pathos+AI+Announces+Strategic+Collaborations+with+Bristol+Myers+Squibb+and+Tempus+AI+to+Advance+AI-Driven+Drug+Development+Beginning+with+Alzheimer%E2%80%99s+Disease+and+Other+Neurological+Conditions/27225611.html Fri, 23 Oct 2026 09:00:00 -0400 BMS BMY TEM http://www.streetinsider.com/Press+Releases/Pathos+AI+Announces+Strategic+Collaborations+with+Bristol+Myers+Squibb+and+Tempus+AI+to+Advance+AI-Driven+Drug+Development+Beginning+with+Alzheimer%E2%80%99s+Disease+and+Other+Neurological+Conditions/27225611.html <ul class="bwlistdisc"> <li> <i>Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement</i> </li> <li> <i>Pathos’s AI expertise and agentic AI platform, Foundry, combined with Bristol Myers Squibb’s (BMS) neuroscience drug development expertise to be applied to understanding disease progression and advancing new therapies</i> </li> <li> <i>BMS leads Pathos’s Series E financing and gains non-exclusive strategic access to Pathos’s AI platform, Pathos Foundry, across its broader portfolio, along with three-year exclusive rights to support its neuroscience development programs</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- Pathos AI, a clinical-stage AI and technology company advancing http://www.streetinsider.com/Press+Releases/Pathos+AI+Announces+Strategic+Collaborations+with+Bristol+Myers+Squibb+and+Tempus+AI+to+Advance+AI-Driven+Drug+Development+Beginning+with+Alzheimer%E2%80%99s+Disease+and+Other+Neurological+Conditions/27225611.html Fri, 23 Oct 2026 09:00:00 -0400 BMS BMY TEM http://www.streetinsider.com/Business+Wire/Pathos+AI+Announces+Strategic+Collaborations+with+Bristol+Myers+Squibb+and+Tempus+AI+to+Advance+AI-Driven+Drug+Development+Beginning+with+Alzheimer%E2%80%99s+Disease+and+Other+Neurological+Conditions/27225611.html <ul class="bwlistdisc"> <li> <i>Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement</i> </li> <li> <i>Pathos’s AI expertise and agentic AI platform, Foundry, combined with Bristol Myers Squibb’s (BMS) neuroscience drug development expertise to be applied to understanding disease progression and advancing new therapies</i> </li> <li> <i>BMS leads Pathos’s Series E financing and gains non-exclusive strategic access to Pathos’s AI platform, Pathos Foundry, across its broader portfolio, along with three-year exclusive rights to support its neuroscience development programs</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- Pathos AI, a clinical-stage AI and technology company advancing http://www.streetinsider.com/Business+Wire/Pathos+AI+Announces+Strategic+Collaborations+with+Bristol+Myers+Squibb+and+Tempus+AI+to+Advance+AI-Driven+Drug+Development+Beginning+with+Alzheimer%E2%80%99s+Disease+and+Other+Neurological+Conditions/27225611.html Fri, 23 Oct 2026 09:00:00 -0400 BMS BMY TEM http://www.streetinsider.com/Press+Releases/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html <p class="bwalignc"> <i>Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences</i> </p><p class="bwalignc"> <i>BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines</i> </p> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com&amp;esheet=54573164&amp;newsitemid=20260720065516&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=94b85fa7d7018397e5469cf36424ab5a" shape="rect">Bristol Myers Squibb</a> (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned http://www.streetinsider.com/Press+Releases/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html Mon, 20 Jul 2026 06:59:00 -0400 BMS BMY O.00000283 http://www.streetinsider.com/Business+Wire/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html <p class="bwalignc"> <i>Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences</i> </p><p class="bwalignc"> <i>BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines</i> </p> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com&amp;esheet=54573164&amp;newsitemid=20260720065516&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=94b85fa7d7018397e5469cf36424ab5a" shape="rect">Bristol Myers Squibb</a> (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned http://www.streetinsider.com/Business+Wire/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html Mon, 20 Jul 2026 06:59:00 -0400 BMS BMY O.00000283 http://www.streetinsider.com/Press+Releases/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html <p class="bwalignc"> <i>Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences</i> </p><p class="bwalignc"> <i>BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines</i> </p> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com&amp;esheet=54573164&amp;newsitemid=20260720065516&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=94b85fa7d7018397e5469cf36424ab5a" shape="rect">Bristol Myers Squibb</a> (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned http://www.streetinsider.com/Press+Releases/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html Mon, 20 Jul 2026 06:59:00 -0400 BMS BMY O.00000283 http://www.streetinsider.com/Business+Wire/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html <p class="bwalignc"> <i>Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences</i> </p><p class="bwalignc"> <i>BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines</i> </p> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com&amp;esheet=54573164&amp;newsitemid=20260720065516&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=94b85fa7d7018397e5469cf36424ab5a" shape="rect">Bristol Myers Squibb</a> (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned http://www.streetinsider.com/Business+Wire/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html Mon, 20 Jul 2026 06:59:00 -0400 BMS BMY O.00000283 http://www.streetinsider.com/Press+Releases/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html <p class="bwalignc"> <i>Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences</i> </p><p class="bwalignc"> <i>BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines</i> </p> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com&amp;esheet=54573164&amp;newsitemid=20260720065516&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=94b85fa7d7018397e5469cf36424ab5a" shape="rect">Bristol Myers Squibb</a> (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned http://www.streetinsider.com/Press+Releases/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html Mon, 20 Jul 2026 06:59:00 -0400 BMS BMY O.00000283 http://www.streetinsider.com/Business+Wire/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html <p class="bwalignc"> <i>Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences</i> </p><p class="bwalignc"> <i>BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines</i> </p> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com&amp;esheet=54573164&amp;newsitemid=20260720065516&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=94b85fa7d7018397e5469cf36424ab5a" shape="rect">Bristol Myers Squibb</a> (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned http://www.streetinsider.com/Business+Wire/Bristol+Myers+Squibb+to+Build+the+Most+Powerful+AI+Factory+in+Life+Sciences+with+NVIDIA/26786755.html Mon, 20 Jul 2026 06:59:00 -0400 BMS BMY O.00000283 http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS